Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.64 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.62 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.62 |
| ▸ | TSHR | P16473 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | PARP1 | P09874 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.55 |
| ▸ | DHODH | Q02127 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.53 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19115277 | 1.00 | ALDH1A1 (0.64) | ALDH1A1MTNR1AMTNR1BTSHRMEN1 | |
| SCHEMBL2406505 | 0.92 | ALDH1A1 (0.76) | ALDH1A1TSHRMEN1KMT2AHTT | |
| SCHEMBL1565743 | 0.92 | ALDH1A1 (0.76) | ALDH1A1TSHRMEN1KMT2AHTT | |
| SCHEMBL21766236 | 0.91 | ALDH1A1 (0.64) | ALDH1A1TSHRMEN1KMT2APARP1 | |
| SCHEMBL5969797 | 0.91 | ALDH1A1 (0.64) | ALDH1A1TSHRMEN1KMT2APARP1 | |
| SCHEMBL7154380 | 0.91 | ALDH1A1 (0.64) | ALDH1A1TSHRMEN1KMT2APARP1 | |
| SCHEMBL7003255 | 0.89 | CA12 (0.65) | ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL5970025 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRMEN1KMT2APARP1 | |
| SCHEMBL17335683 | 0.88 | ALDH1A1 (0.61) | ALDH1A1MTNR1AMTNR1BTSHRMEN1 | |
| SCHEMBL5969969 | 0.88 | ALDH1A1 (0.61) | ALDH1A1TSHRMEN1KMT2APARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4782252-B2 | — | — | 2011-09-28 | — | — | JP | claimed |
| EP-0738149-B1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 2006-11-29 | — | — | EP | claimed |
| US-6528685-B2 | Such as (R)-N-(2-acetamido)-1-aminoindan for treatment of Parkinson's disease, dementia, epilepsy, convulsions, or seizures | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 2003-03-04 | — | — | US | claimed |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | COHEN SASSON (IL) | 2002-06-06 | — | — | US | claimed |
| US-5994408-A | THERAPY FOR PARKINSON'S DISEASE; ANTICONVULSANT | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-11-30 | — | — | US | claimed |
| EP-0738149-A4 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMA (IL) | 1999-10-27 | — | — | EP | claimed |
| US-5914349-A | ANTICONVULSANTS, EPILEPSY AND COGNITIVE AGENTS | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-06-22 | — | — | US | claimed |
| US-5880159-A | TREATING ACUTE NEUROLOGICAL TRAUMATIC DISORDER OR NEUROTRAUMA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-09 | — | — | US | claimed |
| US-5877221-A | TREATING DEMENTIA | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1999-03-02 | — | — | US | claimed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | claimed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | claimed |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | SHY Therapeutics LLC | 2023-09-14 | — | — | US | disclosed |
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC (US) | 2023-01-24 | — | — | US | disclosed |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2021-03-09 | — | — | US | disclosed |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | SHY THERAPEUTICS, INC. | 2020-04-23 | — | — | US | disclosed |
| US-5639913-A | TREATMENT OF PARKINSON'S DISEASE, DEMENTIA, EPILEPSY | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1997-06-17 | — | — | US | disclosed |
| EP-0738149-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-10-23 | — | — | EP | disclosed |
| WO-1996021640-A1 | OPTICALLY ACTIVE AMINOINDANE DERIVATIVES AND PREPARATION THEREOF | TEVA PHARMACEUTICAL INDUSTRIES, LTD. (IL) | 1996-07-18 | — | — | WO | disclosed |
| WO-1995018617-A1 | 1-AMINOINDAN DERIVATIVES AND COMPOSITIONS THEREOF | TEVA PHARMACEUTICAL INDUSTRIES LTD. (IL) | 1995-07-13 | — | — | WO | disclosed |
| CN-1104412-A | Peripheral Vasodilating agent containing N-acylated 4-amino piperidine derivatives as active ingredients | OTSUKA PHARMA CO LTD (JP) | 1995-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11560390-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885MTNR1A 1704/4885MTNR1B 1599/4885 |
| US-20230286997-A1 | Compounds for the Treatment of Cancer and Inflammatory Disease | MAPK6, MAP3K6, MAPK4 | ALDH1A1 2765/4885MTNR1A 1704/4885MTNR1B 1599/4885 |
| US-20200121660-A1 | COMPOUNDS THAT INTERACT WITH THE RAS SUPERFAMILY FOR THE TREATMENT OF CANCERS, INFLAMMATORY DISEASES, RASOPATHIES, AND FIBROTIC DISEASE | HRAS, KRAS, NRAS | ALDH1A1 3448/4885MTNR1A 4052/4885MTNR1B 4028/4885 |
| US-10940139-B2 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | ALDH1A1 3448/4885MTNR1A 4052/4885MTNR1B 4028/4885 |
| US-20020068839-A1 | COMPOSITIONS CONTAINING AND METHODS OF USING 1-AMINOINDAN AND DERIVATIVES THEREOF AND PROCESS FOR PREPARING OPTICALLY ACTIVE 1-AMINOINDAN DERIVATIVES | PARK7, GAP43, PSEN1 | ALDH1A1 384/4885MTNR1A 135/4885MTNR1B 374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.